Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode — APPRAISE  

Schizophrenia Clinical Trial

Official title: Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode

Status Terminated

Clinical Trial Summary

This 12-month study will evaluate the efficacy of aripiprazole lauroxil compared to oral aripiprazole in preventing the re-emergence of psychotic symptoms in patients with a recent onset of schizophrenia.

Clinical Trial Description

This is a single-site 12-month open-label randomized study comparing the efficacy of the FDA-approved long-acting formulation of aripiprazole lauroxil to the efficacy of oral aripiprazole among patients with a recent onset of schizophrenia, schizophreniform, or schizoaffective (depressed) disorder. All assessments and treatment will take place at the UCLA Aftercare Research Program (300 UCLA Medical Plaza, Los Angeles, CA 90095), which is a program that specializes in the treatment and study of individuals with a recent onset of schizophrenia. The primary goal is to evaluate the efficacy of aripiprazole lauroxil compared to oral aripiprazole in preventing the re-emergence of psychotic symptoms in patients with a recent onset of schizophrenia. All patients on oral medications will, at least initially, be treated with oral aripiprazole. ;

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Psychotic Disorders
• Schizoaffective Disorder, Depressive Type
• Schizophrenia
• Schizophreniform Disorder

• NCT number: NCT04203056
• Study type: Interventional
• Source: University of California, Los Angeles
• Status: Terminated
• Phase: Phase 4
• Start date: December 16, 2019
• Completion date: October 1, 2022